{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T14:37:54Z","timestamp":1771511874529,"version":"3.50.1"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s00228-025-03929-0","type":"journal-article","created":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T07:57:06Z","timestamp":1768463826000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Signals of pericardial and myocardial events associated with antiangiogenic drugs: a disproportionality analysis on FAERS\u00ae"],"prefix":"10.1007","volume":"82","author":[{"given":"Francesca Maria","family":"Santoni","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valerio","family":"Ciccone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandra","family":"Flaccavento","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucia","family":"Morbidelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marina","family":"Ziche","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Tuccori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Spini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra","family":"Donnini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,15]]},"reference":[{"issue":"6","key":"3929_CR1","doi-asserted-by":"publisher","first-page":"867","DOI":"10.3390\/ph16060867","volume":"16","author":"V Ciccone","year":"2023","unstructured":"Ciccone V, Ziche M, Spini A, Donnini S (2023) Uncovering knowledge gaps in the safety profile of antiangiogenic drugs in cancer patients: insights from spontaneous reporting systems studies. Pharmaceuticals (Basel) 16(6):867","journal-title":"Pharmaceuticals (Basel)"},{"issue":"7541","key":"3929_CR2","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1038\/nature14119","volume":"519","author":"T Pemovska","year":"2015","unstructured":"Pemovska T, Johnson E, Kontro M, Repasky GA, Chen J, Wells P et al (2015) Axitinib effectively inhibits BCR-ABL1(T315I) with a distinct binding conformation. Nature 519(7541):102\u2013105","journal-title":"Nature"},{"issue":"5","key":"3929_CR3","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1111\/bcp.13873","volume":"85","author":"JH Hughes","year":"2019","unstructured":"Hughes JH, Phelps MA, Upton RN, Reuter SE, Gao Y, Byrd JC et al (2019) Population pharmacokinetics of Lenalidomide in patients with B-cell malignancies. Br J Clin Pharmacol 85(5):924\u2013934","journal-title":"Br J Clin Pharmacol"},{"issue":"10","key":"3929_CR4","doi-asserted-by":"publisher","first-page":"3967","DOI":"10.1158\/0008-5472.CAN-04-2427","volume":"65","author":"P Nyberg","year":"2005","unstructured":"Nyberg P, Xie L, Kalluri R (2005) Endogenous inhibitors of angiogenesis. Cancer Res 65(10):3967\u20133979","journal-title":"Cancer Res"},{"issue":"7","key":"3929_CR5","doi-asserted-by":"publisher","first-page":"3765","DOI":"10.3390\/ijms22073765","volume":"22","author":"F Lopes-Coelho","year":"2021","unstructured":"Lopes-Coelho F, Martins F, Pereira SA, Serpa J (2021) Anti-Angiogenic therapy: current challenges and future perspectives. Int J Mol Sci 22(7):3765","journal-title":"Int J Mol Sci"},{"issue":"9","key":"3929_CR6","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.1007\/s00018-019-03351-7","volume":"77","author":"R Lugano","year":"2020","unstructured":"Lugano R, Ramachandran M, Dimberg A (2020) Tumor angiogenesis: causes, consequences, challenges and opportunities. Cell Mol Life Sci 77(9):1745\u20131770","journal-title":"Cell Mol Life Sci"},{"issue":"4","key":"3929_CR7","doi-asserted-by":"publisher","first-page":"e181","DOI":"10.1002\/mco2.181","volume":"3","author":"GH Liu","year":"2022","unstructured":"Liu GH, Chen T, Zhang X, Ma XL, Shi HS (2022) Small molecule inhibitors targeting the cancers. MedComm 3(4):e181","journal-title":"MedComm"},{"key":"3929_CR8","doi-asserted-by":"publisher","first-page":"1127128","DOI":"10.3389\/fimmu.2023.1127128","volume":"14","author":"Y Wang","year":"2023","unstructured":"Wang Y, Cui C, Deng L, Wang L, Ren X (2023) Cardiovascular toxicity profiles of immune checkpoint inhibitors with or without angiogenesis inhibitors: a real-world pharmacovigilance analysis based on the FAERS database from 2014 to 2022. Front Immunol 14:1127128","journal-title":"Front Immunol"},{"issue":"24","key":"3929_CR9","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1136\/heartjnl-2018-313726","volume":"104","author":"SJH Dobbin","year":"2018","unstructured":"Dobbin SJH, Cameron AC, Petrie MC, Jones RJ, Touyz RM, Lang NN (2018) Toxicity of cancer therapy: what the cardiologist needs to know about angiogenesis inhibitors. Heart 104(24):1995\u20132002","journal-title":"Heart"},{"key":"3929_CR10","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.ctrv.2016.12.002","volume":"53","author":"H Abdel-Qadir","year":"2017","unstructured":"Abdel-Qadir H, Ethier JL, Lee DS, Thavendiranathan P, Amir E (2017) Cardiovascular toxicity of angiogenesis inhibitors in treatment of malignancy: A systematic review and meta-analysis. Cancer Treat Rev 53:120\u2013127","journal-title":"Cancer Treat Rev"},{"key":"3929_CR11","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1038\/s41698-018-0056-z","volume":"2","author":"RM Touyz","year":"2018","unstructured":"Touyz RM, Herrmann J (2018) Cardiotoxicity with vascular endothelial growth factor inhibitor therapy. NPJ Precis Oncol 2:13","journal-title":"NPJ Precis Oncol"},{"issue":"2","key":"3929_CR12","first-page":"366","volume":"13","author":"D Mihalcea","year":"2023","unstructured":"Mihalcea D, Memis H, Mihaila S, Vinereanu D (2023) Cardiovascular toxicity induced by vascular endothelial growth factor inhibitors. Life (Basel) 13(2):366","journal-title":"Life (Basel)"},{"issue":"2","key":"3929_CR13","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s11523-009-0110-4","volume":"4","author":"K Kelly","year":"2009","unstructured":"Kelly K, Swords R, Mahalingam D, Padmanabhan S, Giles FJ (2009) Serosal inflammation (pleural and pericardial effusions) related to tyrosine kinase inhibitors. Target Oncol 4(2):99\u2013105","journal-title":"Target Oncol"},{"issue":"4","key":"3929_CR14","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1007\/s11523-021-00817-2","volume":"16","author":"A Goldman","year":"2021","unstructured":"Goldman A, Bomze D, Dankner R, Fourey D, Boursi B, Arad M et al (2021) Cardiovascular toxicities of antiangiogenic tyrosine kinase inhibitors: A Retrospective, pharmacovigilance study. Target Oncol 16(4):471\u2013483","journal-title":"Target Oncol"},{"issue":"1","key":"3929_CR15","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1042\/CS20200305","volume":"135","author":"SJH Dobbin","year":"2021","unstructured":"Dobbin SJH, Petrie MC, Myles RC, Touyz RM, Lang NN (2021) Cardiotoxic effects of angiogenesis inhibitors. Clin Sci (Lond) 135(1):71\u2013100","journal-title":"Clin Sci (Lond)"},{"key":"3929_CR16","doi-asserted-by":"publisher","first-page":"1278166","DOI":"10.3389\/fcell.2023.1278166","volume":"11","author":"JD Allbritton-King","year":"2023","unstructured":"Allbritton-King JD, Garc\u00eda-Carde\u00f1a G (2023) Endothelial cell dysfunction in cardiac disease: driver or consequence? Front Cell Dev Biol 11:1278166. https:\/\/doi.org\/10.3389\/fcell.2023.1278166PMID: 37965580; PMCID: PMC10642230","journal-title":"Front Cell Dev Biol"},{"issue":"21","key":"3929_CR17","doi-asserted-by":"publisher","first-page":"5315","DOI":"10.3390\/cancers14215315","volume":"14","author":"A Spini","year":"2022","unstructured":"Spini A, Ciccone V, Rosellini P, Ziche M, Lucenteforte E, Salvo F et al (2022) Safety of Anti-Angiogenic drugs in pediatric patients with solid tumors: A systematic review and Meta-Analysis. Cancers (Basel) 14(21):5315","journal-title":"Cancers (Basel)"},{"issue":"6","key":"3929_CR18","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1007\/s40264-024-01423-7","volume":"47","author":"M Fusaroli","year":"2024","unstructured":"Fusaroli M, Salvo F, Begaud B, AlShammari TM, Bate A, Battini V et al (2024) The reporting of a disproportionality analysis for drug safety signal detection using individual case safety reports in PharmacoVigilance (READUS-PV): explanation and elaboration. Drug Saf 47(6):585\u2013599","journal-title":"Drug Saf"},{"issue":"6","key":"3929_CR19","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1007\/s40264-024-01421-9","volume":"47","author":"M Fusaroli","year":"2024","unstructured":"Fusaroli M, Salvo F, Begaud B, AlShammari TM, Bate A, Battini V et al (2024) The reporting of a disproportionality analysis for drug safety signal detection using individual case safety reports in PharmacoVigilance (READUS-PV): development and statement. Drug Saf 47(6):575\u2013584","journal-title":"Drug Saf"},{"issue":"6","key":"3929_CR20","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1002\/pds.1746","volume":"18","author":"E Poluzzi","year":"2009","unstructured":"Poluzzi E, Raschi E, Moretti U, De Ponti F (2009) Drug-induced Torsades de pointes: data mining of the public version of the FDA adverse event reporting system (AERS). Pharmacoepidemiol Drug Saf 18(6):512\u2013518","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"7","key":"3929_CR21","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1158\/1940-6207.CAPR-24-0085","volume":"17","author":"A Albini","year":"2024","unstructured":"Albini A, Noonan DM, Corradino P, Magnoni F, Corso G (2024) The past and future of angiogenesis as a target for cancer therapy and prevention. Cancer Prev Res (Phila) 17(7):289\u2013303","journal-title":"Cancer Prev Res (Phila)"},{"issue":"2","key":"3929_CR22","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.ajem.2016.10.039","volume":"35","author":"M Laufer-Perl","year":"2017","unstructured":"Laufer-Perl M, Havakuk O, Shacham Y, Steinvil A, Letourneau-Shesaf S, Chorin E, Keren G, Arbel Y (2017) Sex-based differences in prevalence and clinical presentation among pericarditis and myopericarditis patients. Am J Emerg Med 35(2):201\u2013205. https:\/\/doi.org\/10.1016\/j.ajem.2016.10.039Epub 2016 Oct 18. PMID: 27836311","journal-title":"Am J Emerg Med"},{"key":"3929_CR23","doi-asserted-by":"publisher","first-page":"4685288","DOI":"10.1155\/2022\/4685288","volume":"2022","author":"V Shakirova","year":"2022","unstructured":"Shakirova V, Khaertynova I, Markelova M, Tarlinton R, Behnke J, Martynova E, Garanina E, Rizvanov A, Khaiboullina S (2022) Serum cytokine alterations associated with age of patients with nephropathia epidemica. Biomed Res Int 2022:4685288. https:\/\/doi.org\/10.1155\/2022\/4685288PMID: 35059462; PMCID: PMC8766188","journal-title":"Biomed Res Int"},{"issue":"3","key":"3929_CR24","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1161\/CIRCRESAHA.122.321504","volume":"132","author":"S Tousif","year":"2023","unstructured":"Tousif S, Singh AP, Umbarkar P, Galindo C, Wheeler N, Toro Cora A, Zhang Q, Prabhu SD, Lal H (2023) Ponatinib drives cardiotoxicity by S100A8\/A9-NLRP3-IL-1\u03b2 mediated inflammation. Circ Res 132(3):267\u2013289 Epub 2023 Jan 10. PMID: 36625265; PMCID: PMC9898181","journal-title":"Circ Res"},{"issue":"5","key":"3929_CR25","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1093\/cvr\/cvz006","volume":"115","author":"AP Singh","year":"2019","unstructured":"Singh AP, Glennon MS, Umbarkar P, Gupte M, Galindo CL, Zhang Q, Force T, Becker JR, Lal H (2019) Ponatinib-induced cardiotoxicity: delineating the signalling mechanisms and potential rescue strategies. Cardiovasc Res 115(5):966\u2013977. https:\/\/doi.org\/10.1093\/cvr\/cvz006PMID: 30629146; PMCID: PMC6452321","journal-title":"Cardiovasc Res"},{"issue":"15","key":"3929_CR26","doi-asserted-by":"publisher","first-page":"2777","DOI":"10.1158\/0008-5472.CAN-21-3652","volume":"82","author":"AP Hnatiuk","year":"2022","unstructured":"Hnatiuk AP, Bruyneel AAN, Tailor D, Pandrala M, Dheeraj A, Li W, Serrano R, Feyen DAM, Vu MM, Amatya P, Gupta S, Nakauchi Y, Morgado I, Wiebking V, Liao R, Porteus MH, Majeti R, Malhotra SV, Mercola M (2022) Reengineering Ponatinib to minimize cardiovascular toxicity. Cancer Res 82(15):2777\u20132791. https:\/\/doi.org\/10.1158\/0008-5472.CAN-21-3652PMID: 35763671; PMCID: PMC9620869","journal-title":"Cancer Res"},{"key":"3929_CR27","unstructured":"Study Results | Ponatinib in Participants With Resistant Chronic Phase Chronic Myeloid Leukemia (CP-CML) to Characterize the Efficacy and Safety of a Range of Doses | ClinicalTrials.gov [Internet]. [cited 2024 Sep 29]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT02467270?tab=results"},{"key":"3929_CR28","unstructured":"Study Results | Ponatinib for Chronic Myeloid Leukemia (CML) Evaluation and Ph\u2009+\u2009Acute Lymphoblastic Leukemia (ALL) | ClinicalTrials.gov [Internet]. [cited 2024 Sep 29]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT01207440?tab=results#adverse-events"},{"key":"3929_CR29","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.ijcard.2020.05.077","volume":"316","author":"AP Singh","year":"2020","unstructured":"Singh AP, Umbarkar P, Tousif S, Lal H (2020) Cardiotoxicity of the BCR-ABL1 tyrosine kinase inhibitors: emphasis on Ponatinib. Int J Cardiol 316:214\u2013221","journal-title":"Int J Cardiol"},{"key":"3929_CR30","first-page":"29","volume":"18","author":"S Donnini","year":"2022","unstructured":"Donnini S, Filippelli A, Ciccone V, Spini A, Ristori E, Ziche M, Morbidelli L (2022) Antiangiogenic drugs: chemosensitizers for combination cancer therapy. Cancer Sensitizing Agents Chemother 18:29\u201366","journal-title":"Cancer Sensitizing Agents Chemother"},{"key":"3929_CR31","unstructured":"sutent-epar-product -information_en.pdf [Internet]. [cited 2023 Apr 5]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/sutent-epar-product-information_en.pdf"},{"key":"3929_CR32","unstructured":"iclusig-epar-product -information_en.pdf [Internet]. [cited 2023 Apr 5]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/iclusig-epar-product-information_en.pdf"},{"key":"3929_CR33","first-page":"1111","volume":"6","author":"KE Price","year":"2013","unstructured":"Price KE, Saleem N, Lee G, Steinberg M (2013) Potential of Ponatinib to treat chronic myeloid leukemia and acute lymphoblastic leukemia. Onco Targets Ther 6:1111\u20131118","journal-title":"Onco Targets Ther"},{"issue":"7","key":"3929_CR34","doi-asserted-by":"publisher","first-page":"654","DOI":"10.5152\/akd.2014.5397","volume":"14","author":"I Y\u0131ld\u0131z","year":"2014","unstructured":"Y\u0131ld\u0131z I, Varol U, \u015een F, K\u0131l\u0131\u00e7 L (2014) Cardiac tamponade in a patient treated by Sunitinib for metastatic renal cell carcinoma. Anadolu Kardiyol Derg 14(7):654\u2013656","journal-title":"Anadolu Kardiyol Derg"},{"key":"3929_CR35","doi-asserted-by":"publisher","first-page":"x3","DOI":"10.1093\/annonc\/mdm408","volume":"18","author":"JG Christensen","year":"2007","unstructured":"Christensen JG (2007) A preclinical review of sunitinib, a multitargeted receptor tyrosine kinase inhibitor with anti-angiogenic and antitumour activities. Ann Oncol 18:x3\u201310","journal-title":"Ann Oncol"},{"issue":"187","key":"3929_CR36","doi-asserted-by":"publisher","first-page":"187ra69","DOI":"10.1126\/scitranslmed.3005066","volume":"5","author":"V Chintalgattu","year":"2013","unstructured":"Chintalgattu V, Rees ML, Culver JC, Goel A, Jiffar T, Zhang J et al (2013) Coronary microvascular pericytes are the cellular target of Sunitinib malate-induced cardiotoxicity. Sci Transl Med 5(187):187ra69","journal-title":"Sci Transl Med"},{"issue":"29","key":"3929_CR37","doi-asserted-by":"publisher","first-page":"4708","DOI":"10.1200\/JCO.2007.15.9566","volume":"26","author":"EEW Cohen","year":"2008","unstructured":"Cohen EEW, Rosen LS, Vokes EE, Kies MS, Forastiere AA, Worden FP et al (2008) Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study. J Clin Oncol 26(29):4708\u20134713","journal-title":"J Clin Oncol"},{"key":"3929_CR38","unstructured":"cabometyx-epar-product -information_en.pdf [Internet]. [cited 2023 Jun 10]. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/cabometyx-epar-product-information_en.pdf"},{"key":"3929_CR39","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.ejca.2021.07.023","volume":"157","author":"Q Liu","year":"2021","unstructured":"Liu Q, Yu Y, Lin J, Wang Y, Ai L, Li Q et al (2021) Treatment strategy for myocarditis in patients using immune checkpoint inhibitors or combined anti-vascular endothelial growth factor therapy by clinical severity. Eur J Cancer 157:10\u201320","journal-title":"Eur J Cancer"},{"issue":"12","key":"3929_CR40","doi-asserted-by":"publisher","first-page":"3348","DOI":"10.1111\/bcp.16237","volume":"90","author":"Y Kanbayashi","year":"2024","unstructured":"Kanbayashi Y, Kobayashi S, Kojima A, Wakabayashi H, Shimizu T, Uchida M (2024) Disproportionality analysis of cardiac adverse events associated with lenvatinib using the Japanese adverse drug event report database. Br J Clin Pharmacol 90(12):3348\u20133354. https:\/\/doi.org\/10.1111\/bcp.16237Epub 2024 Sep 2. PMID: 39219554","journal-title":"Br J Clin Pharmacol"},{"issue":"10","key":"3929_CR41","doi-asserted-by":"publisher","first-page":"e006635","DOI":"10.1161\/JAHA.117.006635","volume":"6","author":"TJ Stuhlmiller","year":"2017","unstructured":"Stuhlmiller TJ, Zawistowski JS, Chen X, Sciaky N, Angus SP, Hicks ST et al (2017) Kinome and transcriptome profiling reveal broad and distinct activities of Erlotinib, Sunitinib, and Sorafenib in the mouse heart and suggest cardiotoxicity from combined signal transducer and activator of transcription and epidermal growth factor receptor Inhibition. J Am Heart Assoc 6(10):e006635","journal-title":"J Am Heart Assoc"},{"issue":"12","key":"3929_CR42","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","volume":"380","author":"BI Rini","year":"2019","unstructured":"Rini BI, Plimack ER, Stus V, Gafanov R, Hawkins R, Nosov D et al (2019) Pembrolizumab plus axitinib versus Sunitinib for advanced Renal-Cell carcinoma. N Engl J Med 380(12):1116\u20131127","journal-title":"N Engl J Med"},{"issue":"1","key":"3929_CR43","doi-asserted-by":"publisher","first-page":"17324","DOI":"10.1038\/s41598-021-96467-5","volume":"11","author":"T Makunts","year":"2021","unstructured":"Makunts T, Saunders IM, Cohen IV, Li M, Moumedjian T, Issa MA et al (2021) Myocarditis occurrence with cancer immunotherapy across indications in clinical trial and post-marketing data. Sci Rep 11(1):17324","journal-title":"Sci Rep"},{"issue":"5","key":"3929_CR44","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1536\/ihj.17-461","volume":"59","author":"M Takada","year":"2018","unstructured":"Takada M, Yasui T, Oka T, Shioyama W, Kuroda T, Nakai Y et al (2018) Aortic dissection and cardiac dysfunction emerged coincidentally during the Long-Term treatment with angiogenesis inhibitors for metastatic renal cell carcinoma. Int Heart J 59(5):1174\u20131179","journal-title":"Int Heart J"},{"issue":"1","key":"3929_CR45","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1093\/jnci\/djp440","volume":"102","author":"A Albini","year":"2010","unstructured":"Albini A, Pennesi G, Donatelli F, Cammarota R, De Flora S, Noonan DM (2010) Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention. J Natl Cancer Inst 102(1):14\u201325","journal-title":"J Natl Cancer Inst"},{"issue":"1","key":"3929_CR46","first-page":"3","volume":"8","author":"ZL Brumberger","year":"2022","unstructured":"Brumberger ZL, Branch ME, Klein MW, Seals A, Shapiro MD, Vasu S (2022) Cardiotoxicity risk factors with immune checkpoint inhibitors. Cardiooncology 8(1):3","journal-title":"Cardiooncology"},{"issue":"7","key":"3929_CR47","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1007\/s11936-018-0654-7","volume":"20","author":"AK Ghosh","year":"2018","unstructured":"Ghosh AK, Crake T, Manisty C, Westwood M (2018) Pericardial disease in cancer patients. Curr Treat Options Cardiovasc Med 20(7):60","journal-title":"Curr Treat Options Cardiovasc Med"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-025-03929-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-025-03929-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-025-03929-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T13:39:17Z","timestamp":1771508357000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-025-03929-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":47,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["3929"],"URL":"https:\/\/doi.org\/10.1007\/s00228-025-03929-0","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"25 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Patient consent"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"26"}}